https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29691 n = 39), rivaroxaban, (n = 56) or apixaban levels (n = 22) between February 2013 and November 2015 were analysed and compared to two different commercial drug specific calibrators from different manufacturers for each DOAC. Our results show that dabigatran (Hyphen and Technoclone) and rivaroxaban (Stago) calibrators tend to overestimate the APTT but are similar to patient samples for PT. A cut-off DOAC level of 50 ng/mL based on results from patient samples within the laboratory can be used as the lower limit which will result in prolongation of APTT for dabigatran (sensitivity 96%, n = 25) and PT for rivaroxaban (sensitivity 97%, n = 29), respectively. Individual laboratories should be familiar with the sensitivity of their coagulation reagents to different DOACs including differences between patient samples versus different commercial drug specific calibrators.]]> Wed 11 Apr 2018 15:02:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36679 Thrombosis Research, Vol. 179, p. 28-30.]]> Tue 23 Jun 2020 15:03:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39994 Fri 01 Jul 2022 13:35:31 AEST ]]>